October 1st, 2021
Cepheid’s mission is delivering A Better Way to improve patient outcomes by enabling access to molecular diagnostic testing everywhere. Cepheid is the name behind GeneXpert® systems and Xpert® tests that deliver fast, accurate, and reliable test results. We at Cepheid are proud to deliver innovative solutions to help Canadian communities provide molecular PCR testing you can trust.
Beginning October 1, 2021, Cepheid will begin direct commercial operations in Canada under its own business entity, Cepheid Canada (Cepheid Canada). This includes providing direct service and support to our customers as well as establishing a Canadian headquarters in Markham, Ontario. Cepheid has built an incredible team of diagnostics professionals in Canada who are eager to partner with you and committed to ensuring a seamless transition.
In the interim, please consider it business as usual in that Inter Medico will continue to deliver the high-quality support and services you have learned to expect until the transition date at the end of September.
About Cepheid: Lab-quality tests for hospitals,
ER, clinics, nursing homes, and other settings
Cepheid develops, manufactures, and markets industry-leading molecular diagnostic tests and test systems. These include fast, accurate, and easy to use tests for SARS-CoV-2, the virus causing COVID-19, Flu, MRSA, tuberculosis, and other healthcare-associated infections, sexual health and oncology diseases.
To learn more, sign-up to receive communications from the Cepheid Canada team.
Based in Sunnyvale, Calif., Cepheid is a leading molecular diagnostics company that is an operating company within Danaher Corporation's (NYSE: DHR) Diagnostics platform. Cepheid is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated molecular diagnostic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer.